HIGHLIGHTS
- who: MDPI from the Cancer Science Institute of Singapore, Singapore, Singapore Harvard Stem Cells Institute, Harvard Medical School, Boston, MA, USA have published the paper: Type of the Paper (Article, in the Journal: Cells 2022, 11, 2601. of /2022/
- what: Despite the evident role of SALL4 in tumorigenesis and therapy resistance, no therapeutic targeting SALL4 are currently on the market.
- how: CIRSPR data showed that SALL4 is an essential driver node with an overall dependency score of -0.13325 among 789 different cancer cell lines . To expand the scope of SALL4 targeted therapy . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.